{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:43:50Z","timestamp":1764510230923},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2001,12]]},"abstract":"<jats:p>This study was designed to assess the efficacy and safety of substituting cisplatin with oxaliplatin in the DHAP (dexamethasone, cytarabine and cisplatin) regimen for patients with relapsed or refractory non\u2010Hodgkin's lymphoma. Twenty\u2010four evaluable patients with intermediate or high\u2010grade non\u2010Hodgkin's lymphoma were treated at 3\u2010weekly intervals with oxaliplatin (130\u2003mg\/m<jats:sup>2<\/jats:sup>, d\u20031), cytarabine (2\u2003g\/m<jats:sup>2<\/jats:sup> for two doses, d\u20032) and dexamethasone (40\u2003mg, d\u20031\u20134). The median age of the patients was 58 (range 18\u201370). Histological subtypes were diffuse large B cell, 20; mantle cell, two; anaplastic large cell, one; and peripheral T cell, one. The overall objective response rate (RR) was 50% [95% confidence interval (CI)\u2003=\u200329\u201371%] including four complete responses and eight partial responses. RR for those patients treated at first relapse was higher than those treated at second and subsequent relapse (77% versus 29%). Grade 3 and 4 toxicity was mainly haematological: anaemia 17%, neutropenia 75% and thrombocytopenia 75%. No grade 4 non\u2010haematological toxicity was reported. No significant renal and neurotoxicity was demonstrated. Median survival was 10\u00b76\u2003months. Probabilities of 1\u2010year progression\u2010free survival and overall survival were 47% (95% CI\u2003=\u200326\u201366%) and 50% (95% CI\u2003=\u200323\u201372%) respectively. In conclusion, dexamethasone, cytarabine and oxaliplatin (DHAX) is a novel combination in salvage therapy for relapsed or refractory non\u2010Hodgkin's lymphoma. It has clinically significant activity with an acceptable toxicity profile. Lack of renal toxicity makes DHAX an attractive cytoreductive regimen before high\u2010dose chemotherapy.<\/jats:p>","DOI":"10.1046\/j.1365-2141.2001.03181.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:40:31Z","timestamp":1047364831000},"page":"786-792","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["An oxaliplatin\u2010based chemotherapy in patients with relapsed or refractory intermediate and high\u2010grade non\u2010Hodgkin's lymphoma"],"prefix":"10.1111","volume":"115","author":[{"given":"Ian","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suad","family":"Ageli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kairen","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Catovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"96","article-title":"Oxaliplatin in colorectal cancer: an overview","volume":"27","author":"Armand J.P.","year":"2000","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2739"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008319600648"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010500"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008200825886"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008334215414"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1200\/JCO.2000.18.11.2293","article-title":"Phase I, dose\u2010finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer","volume":"18","author":"Fizazi K.","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_10_1","first-page":"891","article-title":"Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5\u2010fluorouracil in colorectal cancer patients","volume":"3","author":"Gamelin E.","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008310708853"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.136"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1993.393"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010489"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00068-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(98)00007-0"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1193"},{"key":"e_1_2_6_21_1","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond E.","year":"1998","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)81490-6"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70471-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1264::AID-CNCR1127>3.0.CO;2-X"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00122-6"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050338"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.1.117.117"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.6.1169"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03181.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.2001.03181.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.2001.03181.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:29:56Z","timestamp":1697455796000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.2001.03181.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["10.1046\/j.1365-2141.2001.03181.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03181.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,12]]},"assertion":[{"value":"2001-12-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}